Skip to main content

Table 1 Clinic-pathological characteristics of the explorative cohort

From: Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients

Number of patients

10

Age (mean ± SD)

65.30 ± 9.67

Gender

Female

Cancer type

Ovarian cancer

BMI (Kg/m2) (mean ± SD)

25.16 ± 8.86

ECOG

 

 0

6 (60%)

 1

2 (20%)

 2

1 (10%)

 3

1 (10%)

Histology

 

 High-grade serous carcinoma

8 (80%)

 Low-grade serous carcinoma

1 (10%)

 Clear cell carcinoma

1 (10%)

Federation of gynecology and obstetrics stage (FIGO)

 

 Stage II

1 (10%)

 Stage III

6 (60%)

 Stage IV

3 (30%)

T Stage

 

 T2

1 (10%)

 T3

7 (70%)

 Tx

2 (20%)

N Stage

 

 N0

3 (30%)

 N1

5 (50%)

 Nx

2 (20%)

M Stage

 

 M0

4 (40%)

 M1

2 (20%)

 Mx

4 (40%)

Primary surgery

 

 Stage II

1 (100%)

 Stage III

5 (83%)

 Stage IV

2 (66%)

Residual disease

 

 Stage II

R0: 1 (100%)

 Stage III

R0: 2 (33%), R1: 3 (60%), R2: 1 (17%)

 Stage IV

R2: 3 (100%)

  1. Residual disease after surgery was reported as R0, R1, and R2. R0 was defined as no macroscopic residual disease. R1 and R2 were defined as macroscopic residual disease with a maximal diameter of < 1 cm and > 1 cm, respectively.